Compound News and Research

RSS

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9.

29 May 2015

Study points to the importance of addressing health-related needs of ex-prisoners

Ex-prisoners with a history of risky drug use, mental illness or poverty are more likely to end up back behind bars. Those who are obese, are chronically ill or have attempted suicide are more likely to remain in the community. These are some of the findings from an exploratory study into health-related factors that could be used to predict whether a person released from prison will end up in custody again.

29 May 2015

DigiPath, Euphoria partner to set highest medical marijuana patient safety and education standards

DigiPath Labs of Las Vegas, a subsidiary of DigiPath, Inc., has entered into a one-year agreement with Euphoria Wellness to conduct comprehensive safety and potency tests on the products Euphoria will sell in its Las Vegas medical marijuana dispensary.

28 May 2015

Reductions in federal support, clinical revenue may impact clinical medicine

Reductions in federal support and clinical revenue not only jeopardize biomedical research at academic medical centers, but may ultimately impact clinical medicine according to an opinion piece in the journal Science Translational Medicine.

28 May 2015

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Phase I/II clinical trial results reported at the American Society for Clinical Oncology (ASCO) Annual Meeting 2015 show promising results for investigational drug brigatinib against ALK+ non-small cell lung cancer (NSCLC), with 58 of 78 ALK+ patients responding to treatment, including 50 of 70 patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.

28 May 2015

Understanding the antimicrobial action of borrelidin: an interview with Dr Min Guo, TSRI

Borrelidin is a naturally occurring antibiotic isolated from the Streptomyces species and initially from Streptomyces rochei in 1949. It is called Borrelidin because it was firstly discovered as having anti-Borrelia activity. Borrelia is a type of bacteria...

27 May 2015

Aflatoxin exposure associated with increased risk of gallbladder cancer

In a small study in Chile that included patients with gallbladder cancer, exposure to aflatoxin (a toxin produced by mold) was associated with an increased risk of gallbladder cancer, according to a study in the May 26 issue of JAMA.

27 May 2015

GHIT Fund expands investments in leishmaniasis, diagnostic tests

The Global Health Innovative Technology Fund, which in the last two years has funded almost $32 million for innovative tools to tackle global infectious diseases, today announced additional investments of nearly $11 million that bring its portfolio to approximately $43 million.

22 May 2015

Chemical compound shows promise in treating rheumatoid arthritis

Montana State University researchers and their collaborators have published their findings about a chemical compound that shows potential for treating rheumatoid arthritis.

22 May 2015

Nanoparticle-based therapy effective in treating mice with multiple myeloma

Researchers have designed a nanoparticle-based therapy that is effective in treating mice with multiple myeloma, a cancer of immune cells in the bone marrow.

21 May 2015

Johns Hopkins researchers identify new therapy to treat lung cancer

A multidisciplinary team led by Johns Hopkins researcher Venu Raman, Ph.D., with notable contributions from Guus Bol, Farhad Vesuna and Phuoc Tran of Johns Hopkins, has identified a new therapy for lung cancer, the most common cancer worldwide. The therapy has been in development for six years and involves a first-in-class molecule designed by the team.

20 May 2015

OSU researchers find promising approach to treating epithelial cancer

Researchers at Oregon State University are pursuing a new concept in treatment of epithelial cancer, especially head and neck cancer, by using two promising "analogs" of an old compound that was once studied as a potent anti-tumor agent, but long ago abandoned because it was too toxic.

19 May 2015

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Corcept Therapeutics Incorporated, a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced results of a multi-center Phase 1/2 dose-escalation study of mifepristone and chemotherapy drug eribulin (Halaven) that show it is well tolerated and clinically active in patients with triple-negative breast cancer.

15 May 2015

Gadusol compound can provide a systemic sunscreen to humans

Researchers have discovered why many animal species can spend their whole lives outdoors with no apparent concern about high levels of solar exposure: they make their own sunscreen.

14 May 2015

TB Alliance announces start of clinical trial to treat XDR-TB

TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (XDR-TB). It is the first study to test an all-oral drug regimen, comprised of drugs with minimal pre-existing resistance, that has the potential to shorten, simplify, and improve treatment for XDR-TB.

14 May 2015

Contrast auto-injectors gain momentum in western europe

The use of auto-injectors to ensure controlled and efficient contrast delivery for quick and accurate imaging modality diagnosis is gathering momentum in Western Europe...

13 May 2015

Brooks Automation, BioCision recognized with ISBER’s prestigious award for CryoPod Carrier

The CryoPod Carrier, jointly developed by Brooks Automation, a global provider of automated sample storage systems for compound management and biorepositories, and BioCision, LLC, a leader in advanced biomaterial sample handling and standardization tools, has won the 2015 New Product of the Year award from the International Society for Biological and Environmental Repositories.

13 May 2015

Brain protein plays key role in controlling binge drinking

Scientists at The Scripps Research Institute have discovered that a brain protein has a key role in controlling binge drinking in animal models. They found that deleting the gene for this protein in mice ramped up alcohol consumption and prevented the brain from signaling the rewarding properties of alcohol.

12 May 2015

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.

12 May 2015

New method may help determine potential indicator of stress, neurological disorders

A research collaboration between the universities of Oslo and Aarhus has resulted in the development of a new method with diagnostic potential. The new method that combines phase extraction with an enzymatic reaction may eventually be used for an improved and faster screening analysis of isatin as a potential indicator of stress and neurological disorders.

12 May 2015

Compound News and Research

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Study points to the importance of addressing health-related needs of ex-prisoners

DigiPath, Euphoria partner to set highest medical marijuana patient safety and education standards

Reductions in federal support, clinical revenue may impact clinical medicine

Brigatinib drug shows promise against ALK+ non-small cell lung cancer in phase I/II clinical trial

Understanding the antimicrobial action of borrelidin: an interview with Dr Min Guo, TSRI

Aflatoxin exposure associated with increased risk of gallbladder cancer

GHIT Fund expands investments in leishmaniasis, diagnostic tests

Chemical compound shows promise in treating rheumatoid arthritis

Nanoparticle-based therapy effective in treating mice with multiple myeloma

Johns Hopkins researchers identify new therapy to treat lung cancer

OSU researchers find promising approach to treating epithelial cancer

Mifepristone-eribulin combination clinically active in triple-negative breast cancer patients

Gadusol compound can provide a systemic sunscreen to humans

TB Alliance announces start of clinical trial to treat XDR-TB

Contrast auto-injectors gain momentum in western europe

Brooks Automation, BioCision recognized with ISBER’s prestigious award for CryoPod Carrier

Brain protein plays key role in controlling binge drinking

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

New method may help determine potential indicator of stress, neurological disorders

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News